Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK

Key Points

• Miller Howard Investments Inc. increased its stake in GSK PLC by 0.8%, acquiring over 13,000 additional shares during the second quarter, representing 2.0% of its total holdings.
• GSK recently reported earnings of $1.23 per share, exceeding analysts' estimates, with quarterly revenues of $10.64 billion, up 1.3% from the previous year.
• GSK announced a quarterly dividend of $0.4206, reflecting an annualized dividend yield of 4.1% despite a payout ratio of 77.78%.

Miller Howard Investments Inc. NY grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,659,814 shares of the pharmaceutical company's stock after acquiring an additional 13,023 shares during the period. GSK comprises about 2.0% of Miller Howard Investments Inc. NY's investment portfolio, making the stock its 15th biggest position. Miller Howard Investments Inc. NY owned about 0.08% of GSK worth $63,737,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Dodge & Cox lifted its position in shares of GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares in the last quarter. Primecap Management Co. CA raised its position in GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock valued at $995,929,000 after purchasing an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD grew its stake in GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company's stock worth $299,163,000 after purchasing an additional 155,392 shares in the last quarter. Royal Bank of Canada raised its stake in GSK by 5.7% in the 1st quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company's stock worth $293,692,000 after acquiring an additional 411,869 shares during the last quarter. Finally, Equity Investment Corp boosted its holdings in GSK by 5.3% in the 1st quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after buying an additional 211,608 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

GSK stock traded down $0.42 during trading hours on Tuesday, reaching $40.50. 1,823,182 shares of the stock were exchanged, compared to its average volume of 4,989,607. The stock has a 50 day moving average of $38.95 and a two-hundred day moving average of $38.55. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $42.63. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company has a market cap of $82.38 billion, a P/E ratio of 18.74, a price-to-earnings-growth ratio of 2.03 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the prior year, the company posted $0.43 earnings per share. The business's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analyst Upgrades and Downgrades

GSK has been the topic of several analyst reports. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.